The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients
© 2024 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
CYP3A4 activity shows considerable interindividual variability. Although studies indicate 60%-80% is heritable, common single nucleotide variants (SNVs) in CYP3A4 together only explain ~10%. Transcriptional factors, such as the testis-specific Y-encoded-like proteins (TSPYLs) family, have been reported to regulate the expression of CYP enzymes including CYP3A4 in vitro. Here, we investigated the effect of genetic variants in TSPYL on CYP3A4 activity using data from a clinical study and a human liver bank. Five SNVs (rs3828743, rs10223646, rs6909133, rs1204807, and rs1204811) in TSPYL were selected because of a reported effect on CYP3A4 expression in vitro or suggested clinical effect. For the clinical study, whole blood concentrations, clinical data, and DNA were available from 295 kidney transplant recipients participating in the prospective MECANO study. A multivariate pharmacokinetic model adjusted for body weight, steroid treatment, and CYP3A4 genotype was used to assess the effect of the genetic variants on cyclosporine clearance. In multivariate analysis, homozygous carriers of rs3828743 had a 18% lower cyclosporin clearance compared to the wild-type and heterozygous patients (28.72 vs. 35.03 L/h, p = 0.018) indicating a lower CYP3A4 activity and an opposite direction of effect compared to the previously reported increased CYP3A4 expression. To validate, we tested associations between rs3828743 and CYP3A4 mRNA and protein expression as well as enzyme activity with data from a liver bank (n = 150). No association with any of these end points was observed. In conclusion, the totality of evidence is not in support of a significant role for TSPYL SNV rs3828743 in explaining variability in CYP3A4 activity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Clinical and translational science - 17(2024), 2 vom: 24. Feb., Seite e13729 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhai, Qinglian [VerfasserIn] |
---|
Links: |
---|
Themen: |
83HN0GTJ6D |
---|
Anmerkungen: |
Date Completed 22.02.2024 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1111/cts.13729 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368707261 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368707261 | ||
003 | DE-627 | ||
005 | 20240418232617.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240222s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/cts.13729 |2 doi | |
028 | 5 | 2 | |a pubmed24n1379.xml |
035 | |a (DE-627)NLM368707261 | ||
035 | |a (NLM)38380703 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhai, Qinglian |e verfasserin |4 aut | |
245 | 1 | 4 | |a The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2024 | ||
500 | |a Date Revised 17.04.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
520 | |a CYP3A4 activity shows considerable interindividual variability. Although studies indicate 60%-80% is heritable, common single nucleotide variants (SNVs) in CYP3A4 together only explain ~10%. Transcriptional factors, such as the testis-specific Y-encoded-like proteins (TSPYLs) family, have been reported to regulate the expression of CYP enzymes including CYP3A4 in vitro. Here, we investigated the effect of genetic variants in TSPYL on CYP3A4 activity using data from a clinical study and a human liver bank. Five SNVs (rs3828743, rs10223646, rs6909133, rs1204807, and rs1204811) in TSPYL were selected because of a reported effect on CYP3A4 expression in vitro or suggested clinical effect. For the clinical study, whole blood concentrations, clinical data, and DNA were available from 295 kidney transplant recipients participating in the prospective MECANO study. A multivariate pharmacokinetic model adjusted for body weight, steroid treatment, and CYP3A4 genotype was used to assess the effect of the genetic variants on cyclosporine clearance. In multivariate analysis, homozygous carriers of rs3828743 had a 18% lower cyclosporin clearance compared to the wild-type and heterozygous patients (28.72 vs. 35.03 L/h, p = 0.018) indicating a lower CYP3A4 activity and an opposite direction of effect compared to the previously reported increased CYP3A4 expression. To validate, we tested associations between rs3828743 and CYP3A4 mRNA and protein expression as well as enzyme activity with data from a liver bank (n = 150). No association with any of these end points was observed. In conclusion, the totality of evidence is not in support of a significant role for TSPYL SNV rs3828743 in explaining variability in CYP3A4 activity | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Cyclosporine |2 NLM | |
650 | 7 | |a 83HN0GTJ6D |2 NLM | |
650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Transcription Factors |2 NLM | |
650 | 7 | |a CYP3A4 protein, human |2 NLM | |
650 | 7 | |a EC 1.14.14.55 |2 NLM | |
700 | 1 | |a Moes, Dirk Jan A R |e verfasserin |4 aut | |
700 | 1 | |a van Gelder, Teun |e verfasserin |4 aut | |
700 | 1 | |a van der Lee, Maaike |e verfasserin |4 aut | |
700 | 1 | |a Sanders, Jan-Stephan |e verfasserin |4 aut | |
700 | 1 | |a Bemelman, Frederike J |e verfasserin |4 aut | |
700 | 1 | |a de Fijter, Johan W |e verfasserin |4 aut | |
700 | 1 | |a Klein, Kathrin |e verfasserin |4 aut | |
700 | 1 | |a Schwab, Matthias |e verfasserin |4 aut | |
700 | 1 | |a Swen, Jesse J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 17(2024), 2 vom: 24. Feb., Seite e13729 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2024 |g number:2 |g day:24 |g month:02 |g pages:e13729 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.13729 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2024 |e 2 |b 24 |c 02 |h e13729 |